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Abstract 7 
Background: NNRTIs are recommended as part of first-line treatment for HIV-1 in Africa. 8 
However, NNRTI-based regimens are more prone to resistance development than protease 9 
inhibitors (PIs) in a context in which drug interruptions are frequent. The aim of this study was to 10 
compare the efficacy and tolerability of NNRTIs with PIs in HIV-1-infected patients in Guinea-11 
Bissau. 12 
Methods: This open-label randomised, two-arm superiority tal compared the use of two NRTIs 13 
plus either one NNRTI (efavirenz or nevirapine) or one PI (lopinavir/ritonavir) in treatment-naïve 14 
HIV-1-infected adults in the Bissau HIV Cohort (ClinicalTrials.gov, NCT0019235). The primary 15 
endpoint was HIV-1 RNA <400 copies/ml after 12 months of treatment. 16 
Results: Between May 5, 2011 and April 26, 2013, 400 patients were included in the study. In an 17 
intention-to-treat analysis, the proportions of patients with viral suppression were similar in the 18 
NNRTI (65/197 (33.0%)) and PI (68/203 (33.5%)) arms (p=0.92). No PI resistance was detected, 19 
but high-level NNRTI resistance was seen in 17/30 (56.7%) of NNRTI vs. 3/26 (11.5%) of PI-20 
treated patients, p<0.01. After 1 year of follow-up, 65 patients died (16.3%) and 93 were lost to 21 
follow-up (23.3%). There was no difference in mortality (hazard ratio 0.84, 95% CI 0.51-1.36) or 22 
frequency of clinical adverse events between treatmn  arms (NNRTI: 73/197 (37.1%); PI: 69/203 23 
(34.0%); p=0.52).  24 
Conclusion: In patients at an HIV clinic in Guinea-Bissau, treatment with PIs led to less 25 
development of resistance compared with NNRTIs but was not superior in terms of viral 26 
suppression, CD4 cell increment, mortality, or sever  adverse events.  27 
AC
CE
PT
ED
Copyright  2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
 
 
 
 
 
 4
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transcriptase inhibitors, Guinea-Bissau. 2 
 3 
Introduction 4 
Lifelong treatment is still a new concept in parts of Africa, where healthcare systems already face 5 
challenges such as insufficient numbers of healthcare providers, intermittent drug supplies, fear of 6 
stigmatisation, long distance to treatment clinics, and poor medical record registration.1,2 All these 7 
factors increase HIV patients’ risk of treatment failure.  8 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended as part of first-line 9 
treatment for HIV-1 in Africa.3 NNRTIs have a longer elimination half-life than other antiretroviral 10 
treatments (ARTs), which make NNRTI-based regimens more prone to resistance development in a 11 
context of frequent drug interruptions. This problem is even more pronounced in Black Africans, 12 
who more frequently harbour a polymorphism in cytochr me P450 2B6 associated with slower 13 
plasma clearance of efavirenz (EFV).4 14 
Large randomised trials comparing NNRTIs with proteas  inhibitors (PIs) have been conducted in 15 
Europe and the United States of America,5-10 but these results are not generalisable to an African 16 
setting due to differences in genetics, sex distribu ion, and adherence.4,11 Most studies comparing 17 
NNRTIs with PIs in adults that have been conducted in Africa have indicated equivalent efficacy; 18 
however, most of these studies only included women and treatment procedures were supported 19 
economically and practically to a larger extend than is common in the vast majority of centers in 20 
Sub-Saharan Africa. Thus, these trials probably do not reflect the typical reality of HIV treatment 21 
on the African continent.12-15  22 
The aim of this study was to compare the efficacy and tolerability of an NNRTI-based regimen with 23 
those of a PI-based regimen in HIV-1-infected patients in Guinea-Bissau. We hypothesised that PIs 24 
are a better choice as first-line treatment than NNRTIs in Guinea-Bissau. 25 
 26 
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Methods 1 
Study design 2 
This trial, named “PI or NNRTI as first-line HIV treatment in a West African population with low 3 
adherence – the PIONA trial,” was an open-label, randomised, two-arm superiority trial in which 4 
treatment-naïve patients infected with HIV-1 were randomised to a regimen including either an 5 
NNRTI or a PI (ClinicalTrials.gov, NCT0019235). This study was approved by the National Ethics 6 
Committee of Guinea-Bissau (Parecer NCP/No.11/2010). The Danish National Committee on 7 
Biomedical Research Ethics gave its consultative approval (Case No. 1001028). An independent 8 
Data and Safety Monitoring Board reviewed interim analyses from the PIONA trial every six 9 
months.  10 
 11 
Participants 12 
Participants in the PIONA trial were included from the HIV clinic at Hospital National Simão 13 
Mendes in Bissau, the capital of Guinea-Bissau. This clinic is the base of the Bissau HIV Cohort.16 14 
We included all ART-naïve, HIV-1-infected adults ≥18 years of age seen at the clinic during the 15 
study period and who fulfilled the criteria to commence ART according to WHO guidelines (CD4 16 
cell count ≤350 cells/µl and/or clinical signs of immune suppression (WHO clinical stage 3 or 4) 17 
irrespective of CD4 cell count) 17. Exclusion criteria were tuberculosis treatment with rifampicin at 18 
the time of enrolment, co-infection with HIV-2, liver enzyme elevation >5 times the upper normal 19 
limit, cerebral disturbances that complicated the ability to give informed consent, or treatment with 20 
nevirapine (NVP) to prevent mother-to-child transmision of HIV within the past year. Prior to 21 
enrolment, all patients voluntarily provided signed and dated informed consent, or a fingerprint if 22 
illiterate. 23 
 24 
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 6
Randomisation 1 
Computer-generated block randomisation (blocks of 10) was performed with a ratio of 1:1 to 2 
NNRTI-based or PI-based ART after stratification by sex and CD4 cell count (≤200 or >200 3 
cells/µl). Sealed-window envelopes contained information about subsequent treatment. 4 
 5 
Procedures 6 
All patients received two NRTIs according to local guidelines. Patients in the NNRTI treatment arm 7 
further received one NNRTI (EFV 600 mg once daily or NVP 200 mg once daily for the first 2 8 
weeks and 200 mg twice daily subsequently). EFV was given to all males as well as females beyond 9 
childbearing age. Pregnant patients and female patints with childbearing potential were treated 10 
with NVP when CD4 cell count was ≤350 cells/mm3. The PI treatment arm consisted of two NRTIs 11 
and one PI (ritonavir-boosted lopinavir (LPV/r) 400/1 0 mg twice daily). Patients were switched to 12 
second-line treatment based on clinical and/or immunological criteria. Immunological treatment 13 
failure was defined as (1) a fall in CD4 counts to baseline (or below) or (2) CD4 levels persistently 14 
<100 cells/µl 17. In patients undergoing rifampicin-containing tuberculosis treatment, NVP and 15 
LPV/r were replaced by EFV and patients in the LPV/r arm were withdrawn from the study. 16 
Patients who developed grade 3 adverse effects interrup d ART and resumed all medications when 17 
the adverse effect resolved to ≤grade 2 or the offending drug was substituted withou  interrupting 18 
all ART. Patients experiencing grade 4 adverse effects were switched to another regimen. 19 
Study visits occurred at 2 (if NVP was initiated), 4, 8, and 12 weeks after treatment initiation and 20 
every 1-3 months thereafter. Patients were asked about pre-specified adverse events. Adverse events 21 
were graded by severity. Adherence was assessed according to the number of days the patient was 22 
late for their visit. Patients were followed until 12 months after treatment initiation. When patients 23 
were late for their final blood samples, we allowed viral-load measurements and CD4 cell counts 24 
obtained up to 18 months after treatment initiation o be included in analyses. Patients were 25 
considered lost to follow-up if they had not visited the clinic for 6 months. Information on death and 26 
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 7
transfer was collected through conversation with the patient, telephone calls with contact persons, 1 
or from hospital wards. 2 
HIV screening was conducted with the rapid Determine HIV-1/2 assay (Abbott Laboratories, 3 
Abbott Park, IL, USA). Confirmation and discrimination were performed with the SD Bioline HIV 4 
1/2 3.0 rapid test (Standard Diagnostics Inc., Kyonggi-do, South Korea) or the First Response HIV 5 
Card 1-2.0 (PMC Medical, Mumbai, India). HIV type was confirmed via ImmunoComb HIV 1 & 2 6 
BiSpot (Organics, Yavne, Israel) from stored plasma amples in Aarhus, Denmark. Venous blood 7 
samples were collected for biochemical analyses (alanine aminotransferase levels, creatinine, 8 
haemoglobin levels, white blood cell count, and platelets) when the patients initially came to the 9 
clinic and after 1, 3, 6, and 12 months of ART. 10 
CD4 cell counts were measured by flow cytometry using Partec CyFlow® SL_3 cytometer (Partec, 11 
Munster, Germany) before ART initiation and after 3, 6, and 12 months of treatment. HIV-1 viral 12 
load was measured from stored plasma samples (shipped to the Department of Clinical 13 
Biochemistry, Aalborg University Hospital, Denmark) with the Abbott m2000 system (Abbott 14 
Realtime HIV 1, version 9.00; Abbott Molecular Inc., Abbott Park, IL, USA) before ART initiation 15 
and after 6 and 12 months of treatment. The lower level of detection was 75 copies/mL. 16 
Samples from patients experiencing virologic failure were tested for HIV-1 resistance. In addition, 17 
pre-therapy samples were tested for resistance from all patients with resistance after 12 months of 18 
treatment. Genotypic resistance testing of protease and partial reverse-transcriptase (amino acids 6-19 
99 and 1-252, respectively) was performed using an in-house method as described.18 Drug 20 
resistance mutations were examined according to the calibrated population resistance tool version 21 
8.5 (https://hivdb.stanford.edu/hivdb/by-mutations/). Quality control was performed using the 22 
online Quality Control program of the Los Alamos HIV sequence database (hiv.lanl.gov). 23 
Nucleotide sequences reported in this study have been d posited in the Genbank repository 24 
(Accession Numbers: MH476364-MH476446). 25 
 26 
27 
AC
CE
PT
ED
Copyright  2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
 
 
 
 
 
 8
Outcomes 1 
The primary outcome for the study was viral load suppression <400 copies/ml after 12 months of 2 
ART. Secondary key effect measures were viral load suppression <75 copies/ml after 12 months of 3 
ART, CD4 cell count increment of at least 100 cells/µl compared with baseline, adverse events, 4 
adherence, development of resistance and mortality. 5 
 6 
Statistical analyses 7 
We hypothesised that virologic failure occurred more frequently in the NNRTI group, with 8 
estimated failure rates of 12% for PI and 25% for NNRTI 19-21. We therefore calculated the 9 
necessary sample size to be 154 patients in each arm with a power of 80%; we needed to include 10 
386 patients to account for an estimated 20% LTFU. We used the chi-squared test to compare the 11 
proportions of patients who achieved viral suppression after 12 months of treatment. In a post-hoc 12 
analysis, we compared the proportions of patients who achieved a composite endpoint of virologic 13 
failure or death after 12 months of treatment; we also ssessed endpoints after six months of 14 
treatment. Mortality was assessed with Cox proportional hazard models. A post-hoc sensitivity 15 
analysis classified patients lost to follow-up as dea . 16 
The primary analyses were intention-to-treat analyses that included all randomised patients 17 
irrespective of changes in ART. In a modified intentio -to-treat analysis, we excluded patients who 18 
were mistakenly included because they were randomised before information on eligibility was 19 
obtained. An on-treatment analysis of viral suppression included only patients who completed the 20 
study on the initial randomised regimen and had complete outcome assessments. 21 
Median changes in CD4 cell counts from baseline to 1 year of ART were compared with the 22 
Wilcoxon rank sum test. The proportions of patients with CD4 cell count increments of at least 100 23 
cells/µl since baseline and frequencies of adverse vents were compared between treatment arms 24 
with the chi-squared test. Adherence was assessed by calculating the median number of days each 25 
patient was late for their appointment. Comparisons between treatment groups were made with the 26 
Wilcoxon rank sum test. 27 
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 9
All statistical analyses were carried out using Stata IC 13.1 (StataCorp, College Station, TX, USA). 1 
 2 
Role of the funding source 3 
AbbVie Pharmaceuticals donated LPV/r (Aluvia) for the trial. AbbVie had no role in study design, 4 
data collection, or data analysis, but was permitted to review the manuscript and suggest changes. 5 
Final decisions on content were exclusively made by the authors. 6 
 7 
Results 8 
Between May 5, 2011 and April 26, 2013, 400 patients were enrolled in the study (Figure 1). HIV-9 
1-infected patients not included in the study were more likely to have higher baseline CD4 cell 10 
counts and body mass index and were more likely to no  start ART at HIV diagnosis 11 
(Supplementary Table 1, http://links.lww.com/QAI/B199). After randomisation, confirmation of 12 
HIV type led to the exclusion of 3 patients with HIV-2 and 12 patients with HIV-1/2 dual infection 13 
who were initially incorrectly diagnosed with HIV-1. Five patients did not fulfil the inclusion 14 
criteria for other reasons (Figure 1). Results from 380 patients were included in the modified 15 
intention-to-treat analyses. Sixty-five patients died within the first 12 months of treatment. After 16 
completion of 12 months of initial randomised treatment, final viral-load measurements were 17 
obtained for 87 NNRTI-treated patients (44.2%) and 84 PI-treated patients (41.4%; p=0.57). These 18 
patients were included in the on-treatment analyses. 19 
Treatment was halted prematurely for 8/197 NNRTI-trea ed patients (4.1%) and for 12/203 PI-20 
treated patients (5.9%; p=0.40). The main reasons fr topping or switching treatment were start of 21 
tuberculosis treatment (5 patients), HIV-2 or HIV-1/2 dual infection (4 patients), grade 3 or 4 22 
adverse events (4 patients), consent withdrawn/patient wished to withdraw (3 patients), and 23 
immunological treatment failure (2 patients, both in the NNRTI-arm). Another 31 patients fulfilled 24 
the criteria for immunological treatment failure by the end of the study.  25 
Characteristics of the patients are presented in Table 1.  26 
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 10
There were no significant differences in the proportions of patients achieving viral suppression after 1 
6 or 12 months between treatment arms (Table 2). No differences in viral suppression were detected 2 
between NRTI-backbones. Thirty-one of 197 NNRTI-trea ed patients (15.7%) and 26/203 PI-3 
treated patients (12.8%; p=0.40) displayed virologic fa lure with viral load >400 copies/ml after 12 4 
months of treatment. In the on-treatment analysis, 29/87 NNRTI-treated patients (33.3%) and 23/84 5 
PI-treated patients (27.4%) exhibited virologic failure (p=0.40). 6 
Among 57 patients with virologic failure, samples were available for resistance testing in 56 7 
patients. The most common HIV-1 subtype was circulating recombinant form 02_AG (CRF02_AG) 8 
found in 52/56 (92.9%). Genotypes from time of virologic failure revealed that 22/30 (73.3%) in the 9 
NNRTI-arm and 7/26 (26.9%) in the PI-arm had any NRTI or NNRTI mutation, p=<0.01. No cases 10 
of major PI mutations were detected, while NNRTI resistance was common among patients 11 
receiving NNRTI (Table 3). The most common NNRTI mutations were K103N (Supplementary 12 
Table 3, http://links.lww.com/QAI/B199). Among the 25 patients with NNRTI resistance, pre-13 
therapy sequencing was successfully performed in 22 showing pre-therapy NNRTI resistance in six 14 
patients (27.2%), including two patients in the PI-arm. 15 
CD4 cell counts after at least 12 months of treatmen  were available for 96/197 NNRTI-treated 16 
patients and 93/203 PI-treated patients. Although numerically higher in the PI-arm, there were no 17 
significant differences in the increase in absolute CD4 cell count (NNRTI: 167 cells/µl, IQR 37-293 18 
cells/µl; PI: 202 cells/µl, IQR 87-351 cells/µl; p=0.25) and  no between-treatment difference in the 19 
proportion of patients with a CD4 cell-count increment of at least 100 cells/µl (NNRTI: 59/96, 20 
61.5%; PI: 67/93, 72.0%; p=0.12). 21 
After 1 year of follow-up, 35 deaths (17.8%) occurred in the NNRTI-arm and 30 deaths (14.8%) 22 
occurred in the PI-arm (p=0.42). Ninety-three patients (23.3%) were lost to follow-up and 23 23 
patients (5.6%) withdrew. There was no difference in mortality between arms (hazard ratio (HR) 24 
0.84, 95% CI: 0.51-1.36) but patients with baseline CD4 cell count below 200 cells/ µl had higher 25 
mortality than those with higher CD4 cell counts (HR 5.30, 95% CI: 2.42-11.60). In a sensitivity 26 
analysis in which patients lost to follow-up were classified as dead, there was no between-treatment 27 
difference in mortality (LTFU). (HR 0.98, 95% CI: 0.72-1.33). When death and virologic failure 28 
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 11
were treated as a composite endpoint, no difference in outcome was detected between treatment 1 
arms (HR 0.89, 95% CI 0.60-1.32; Supplementary Table 2, http://links.lww.com/QAI/B199). 2 
The frequencies of clinical adverse events were similar in the two treatment arms (NNRTI: 73/197 3 
(37.1%); PI: 69/203 (34.0%); p=0.52). More patients receiving NNRTI experienced a grade 1 or 2 4 
elevation of alanine aminotransferase (ALT) (NNRTI: 47/197 (23.9%); PI: 22/203 (10.8%); 5 
p<0.01) or grade 1 or 2 anaemia compared with patients treated with PI (NNRTI: 98/197 (49.8%); 6 
PI: 80/203 (39.4%); p=0.04) (Table 4). No differenc in ALT were seen according to choice of 7 
NNRTI (EFV: 26/117 (22.2%); NVP: 21/80 (26.3%); p=0.52) 8 
There was a non-significant trend toward lower adherence among patients in the PI-arm than among 9 
patients in the NNRTI-arm (median number of days late per visit, 30 days (IQR 12-45 days) vs. 23 10 
days (IQR 10-41 days), respectively; p=0.07). Patients with resistance mutations had lower 11 
adherence than patients without (median number of days late per visit, 39 days (IQR 30-48 days) vs. 12 
24 days (IQR 10-42 days), respectively; p=0.01). 13 
 14 
Discussion 15 
In this randomised study comparing PIs with NNRTIs conducted among HIV-1-infected patients in 16 
Guinea-Bissau, the risk of developing resistance was lower for patients receiving PIs. However, a 17 
PI-based treatment regimen was not superior to an NNRTI-based treatment regimen after 12 months 18 
of follow-up in terms of virologic suppression, increases in CD4 cell count, or mortality. Both 19 
regimens were well tolerated. There was a trend towards lower adherence for patients receiving PIs, 20 
when compared with NNRTI. 21 
The strength of this trial is that it reflects real life in many African HIV clinics; few data are 22 
reported from these clinics, and few larger, randomised, controlled, treatment trials have been 23 
carried out among adult HIV-infected patients of both sexes in Africa. However, the real-life 24 
approach of this trial also led to several limitations. Data on adherence were insufficient, and only 25 
half of the patients not registered as deceased had a viral-load measurement available after 1 year of 26 
treatment, due to high rate of early mortality in patients with advanced disease as well as LTFU. 27 
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 12
More patients than predicted died or were lost to follow-up, probably reflecting poor health-care 1 
seeking behaviour as well as high levels of resistance. Virologic treatment failure should be 2 
confirmed by a second measurement after assessing adherence, but due to the retrospective 3 
measurements of viral load employed here; this confirmation was not possible and could have 4 
overestimated the true prevalence of treatment failure. The comparison of PI with NNRTI is a 5 
mixed comparison of NVP and EFV. However, previous studies have shown that NVP and EFV 6 
have similar benefits in initial treatment of HIV infection when combined with two NRTIs 22.7 
The number of randomised trials in Sub-Saharan Africa emains low, even though the majority of 8 
people living with HIV are treated in this low-resource setting.23 The OCTANE trials12,24 were 9 
some of the first and largest randomised controlled trials to compare PIs with NNRTIs in Africa, 10 
but only included females. The OCTANE Trial 1 indicated that NVP was inferior to LPV/r as an 11 
initial ART among women with prior single-dose NVP exposure,24 in accordance with later findings 12 
from the Democratic Republic of Congo.25 The OCTANE Trial 2, which included only women with 13 
no prior NVP exposure, revealed that the two treatmnt regimens had equivalent virologic efficacy, 14 
with 17% of NVP and 20% of LPV/r treated subjects experiencing virologic failure or death,26 rates 15 
that were lower than those detected in our study. The South African Phidisa II trial also determined 16 
that EFV and LPV/r were equally effective, without differences in grade 4 adverse events,14 while a 17 
study among pregnant Ugandan women reported equally high proportions of virologic suppression 18 
(91% of EFV vs. 88% of LPV/R treated individuals) through one year postpartum, but more 19 
gastrointestinal adverse events occurred in the LPV/r arm.13 In a randomised four-arm treatment 20 
trial in Senegal, dual therapy with tenofovir and LPV/r was less efficient compared with two NRTIs 21 
plus one NNRTI or with triple NRTI treatment,15 while unboosted atazanavir in combination with 22 
lamivudine and didanosine showed good efficacy and safety in naïve HIV-1-infected patients in 23 
Senegal.27 Most of these large randomised trials were supported economically and practically to a 24 
larger extend than is common in the vast majority of centers in Sub-Saharan Africa and may not be 25 
representative for the situation in most HIV clinics n this area. Overall, in the current investigation, 26 
the rates of viral suppression were only 33% in the int ntion-to-treat population and 69% in the on-27 
treatment population. These rates are lower than those reported in a review of 89 studies from Sub-28 
Saharan Africa in which 78% viral suppression was achieved after six months of ART.28 The lower 29 
proportion of virologic suppression in our study may be explained by poor adherence; patients were 30 
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 13
often late for their appointments, suggesting periods without treatment. As in many similar clinics 1 
in Sub-Saharan Africa, conditions in Bissau are bad regarding the structure of the healthcare 2 
system, economy, mobility of the population, adherence, drug supply, and political stability, all of 3 
which lead to greater risk of treatment failure. Other important reasons for low level of viral 4 
suppression were high rates of LTFU as well as lackof final viral load measurements in all patients.  5 
A recent comprehensive metaanalysis found no difference in clinical or viro-immunological 6 
outcomes between NNRTIs and PIs but did not address resi tance development.10 Genotype 7 
analysis in our study of samples from patients failing treatment revealed NNRTI or NRTI resistance 8 
mutations in nearly three of four patients in the NNRTI-arm, which is even higher than that reported 9 
in other studies,12,29 and reflect poor adherence. The high proportion of pre-therapy resistance can 10 
be due to transmitted resistance or previous ART exposure. However, since pre-therapy resistance 11 
testing was only done in those patients developing treatment failure it is not a true marker of 12 
baseline resistance in Guinea-Bissau. Major PI mutations were not detected similar to findings from 13 
other studies thus PIs can be used again despite treatment failure.29,30 14 
Here, the frequency of mild adverse events was low c mpared with other studies.13 We expected 15 
neurocognitive adverse events to be more common amog patients treated with an NNRTI because 16 
a higher serum concentration of EFV, which is often s en in black Africans, is known to be 17 
associated with adverse events.4 The true prevalence of adverse events may have been 18 
underestimated since patients in Guinea-Bissau are nfamiliar with the concept of describing 19 
adverse events despite being well monitored for this. Furthermore, low adherence may have given 20 
the patients fewer adverse events due to lower serum concentrations. In addition, due to limited 21 
laboratory capacity in Guinea-Bissau it was not possible to monitor lipids. This may reflect reality 22 
in may African HIV clinics. 23 
Patients in the PI-arm of our study were often late for their appointments at the clinic. LPV/r was 24 
prescribed as two tablets twice daily. If patients mi understood this regimen, tablets would remain 25 
when the patients planned to come for their next visi and they would most likely postpone their 26 
visit until they ran out of tablets.  27 
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Patients starting rifampicin-containing treatment for tuberculosis were excluded from the PI-arm of 1 
the current trial due to drug interactions, while patients on tuberculosis treatment were allowed to 2 
continue in the study if they were randomised to NNRTIs. This difference could potentially have 3 
led to an overestimated risk of death in the NNRTI-arm. Overall, few patients were switched from 4 
the randomised treatment in the current trial, yet w  speculate that treatment failure was overlooked. 5 
If lack of viral-load measurements in this study is a marker of poor healthcare-seeking behaviour, 6 
then perhaps these patients are less likely to be virologically suppressed. This issue is expected to 7 
be more problematic for an NNRTI-based regimen thanfor a more robust PI-based regimen, which 8 
may overestimate the proportion of NNRTI-treated patients who were virologically suppressed. The 9 
many reasons for this lack of measurements reflect challenges faced regularly in daily clinical life 10 
in low-resource settings, such as patients not showing up as planned, unstable supplies of reagents, 11 
and breakdowns of CD4 equipment. A multifaceted effort is suggested to be required to improve 12 
adherence and LTFU in Guinea-Bissau, targeting boththe individual, the health care system and the 13 
social environment. However, considering the country’s weak health care system, such a 14 
comprehensive effort is not realistic, leaving peer support and ART groups preceded by education 15 
of local staff as the best proposal for a solitary intervention 31,32. 16 
 17 
We previously described problems with rapid HIV discriminatory tests.33 In the current study, 15 18 
patients turned out to be HIV-2 or HIV-1/2-dually infected and had to be withdrawn from the trial. 19 
Treatment with PIs or integrase inhibitors with a high genetic barrier could be used in a setting with 20 
high HIV-2 prevalence to enable a common first-line treatment. Such a simplified treatment 21 
regimen for all patients will be of high value in a setting where logistical difficulties constantly 22 
threaten regular drug availability and where some patients become dually infected while undergoing 23 
treatment that is only effective against HIV-1.  24 
Conclusions  25 
Among HIV-1-infected patients in Guinea-Bissau, first-line treatment with PIs led to less 26 
development of resistance compared with NNRTIs but was not superior in terms of viral 27 
suppression, CD4 cell increment, mortality, or sever  adverse events. A PI-based treatment may 28 
still be important in a setting in which treatment interruptions are frequent and access to second-line 29 
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treatment is limited. It is possible that accumulated viral resistance against NNRTI will translate 1 
into poorer outcomes during life-long treatment. Promoting adherence and decreasing LTFU must 2 
be a top priority in Bissau. 3 
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Figure 1: Screening, randomization and follow-up of study patients 6 
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Table 1: Baseline characteristics 
 
 NNRTI n=197 PI n=203 
Female sex (%) 123 (62) 127 (63) 
Age in years, median (IQR) 35 (30-42) 36 (30-41) 
CD4 cell count in cells/µl, median (IQR) 
CD4 cell percentage of total lymphocyte count 
139 (68-260) 
6.3 (3.7-11.9) 
153 (71-242) 
7.1 (3.7-11.6) 
HIV-1 RNA in log10 copies/ml, median (IQR) 5.0 (4.4-5.5) 5.1 (4.3-5.7) 
Body mass index in kg/m2, median (IQR) 19.5 (17.4-22.2) 20.2 (17.7-22.7) 
Education (%) 
None 
1-4 years 
5-11 years 
School but level unknown 
Missing 
 
59 (30) 
17 (9) 
115 (58) 
5 (3) 
1 (1) 
 
56 (28) 
21 (10) 
121 (60) 
3 (1) 
2 (1) 
Marital status (%) 
Married 
Divorced 
Widowed 
Single 
Missing 
 
97 (49) 
9 (5) 
33 (17) 
55 (28) 
3 (2) 
 
112 (55) 
13 (6) 
16 (8) 
62 (31) 
0 (0) 
NRTI backbone (%) 
Zidovudine+lamivudine 
Tenofovir+emtricitabine 
Abacavir+lamivudine 
Tenofovir+lamivudine 
Stavudine+lamivudine 
 
109 (55) 
41 (21) 
31 (16) 
15 (8) 
1 (1) 
 
114 (56) 
38 (19) 
30 (15) 
19 (9) 
2 (1) 
NNRTI (%) 
Efavirenz 
Nevirapine 
 
117 (59) 
80 (41) 
 
- 
- 
Marital status (%) 
Married 
Divorced 
Widowed 
Single 
Missing 
 
97 (49) 
9 (5) 
33 (17) 
55 (28) 
3 (2) 
 
112 (55) 
13 (6) 
16 (8) 
62 (31) 
0 (0) 
NRTI: Nucleoside/nucleotide reverse transcriptase inhibitor. NNRTI: Non-nucleoside reverse transcriptase inhibitor. 
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Table 2: Proportion of patients with virologic suppression 
 NNRTI 
n/N (%) 
PI 
n/N (%) 
P-value 
 Intention-to-treat analyses 
HIV-1 RNA <400 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
65/197 (33.0) 
68/197 (34.5) 
 
68/203 (33.5) 
60/203 (29.6) 
 
0.92 
0.29 
HIV-1 RNA <75 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
58/197 (29.4) 
54/197 (27.4) 
 
52/203 (25.6) 
44/203 (21.7) 
 
0.39 
0.19 
 Modified intention-to-treat analyses 
HIV-1 RNA <400 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
61/187 (32.6) 
62/187 (33.2) 
 
66/193 (34.2) 
56/193 (29.0) 
 
0.75 
0.38 
HIV-1 RNA <75 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
54/187 (28.9) 
48/187 (25.7) 
 
50/193 (25.9) 
40/193 (20.7) 
 
0.52 
0.25 
 On-treatment analyses 
HIV-1 RNA <400 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
58/87 (66.7) 
47/87 (54.0) 
 
61/84 (72.6) 
 45/84 (53.6) 
 
0.40 
0.96 
HIV-1 RNA <75 copies/ml 
After 12 months of ART 
After 6-12 months of ART 
 
51/87 (58.6) 
34/87 (39.1) 
 
45/84 (53.6) 
32/84 (38.1) 
 
0.51 
0.90 
n: Number of patients with virologic suppression; N: Total number of patients in the analysis group. 
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Table 3: Summary of drug resistance mutations  
 NNRTI 
n/N (%) 
PI 
n/N (%) 
P-value 
High-level NNRTI resistance at time of virologic failure 17/30 (56.7)  3*/26 (11.5) <0.01 
Low-level NNRTI resistance at time of virologic failure 4/30 (13.3) 1*/26 (3.9) 0.21 
NRTI resistance at time of virologic failure 8/30 (26.7) 5/26 (19.2) 0.51 
Major PI resistance at time of virologic failure 0/3  (0) 0/26 (0) - 
Any resistance at time of virologic failure 22/30 (73.3) 7/26 (26.9) <0.01 
Baseline resistance** 4/30 (13.3%) 2/26 (7.7%) 0.50 
*All females. Two with pre-therapy resistance. ** Baseline resistance testing was only performed in patients 
where any mutations were detected at time of virologic failure. 
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Table 4: Adverse events 
 NNRTI 
n=197 
PI 
n=203 
P-value 
Any grade 1 or 2 sign or symptom, n (%) 
  Diarrhoea 
  Nausea/vomiting 
  Impaired cognition or memory 
  Insomnia 
63 (32.0) 
19 (9.6) 
16 (8.1) 
4 (2.0) 
13 (6.6) 
63 (31.0) 
15 (7.4) 
21 (10.3) 
2 (1.0) 
10 (4.9) 
0.84 
0.42 
0.44 
0.39 
0.47 
Any grade 3 or 4 sign or symptom, n (%) 
  Diarrhoea 
  Nausea/vomiting 
  Impaired cognition or memory 
  Insomnia 
13 (6.6) 
4 (2.0) 
4 (2.0) 
0 (0) 
1 (0.5) 
9 (4.4) 
2 (1.0) 
3 (1.5) 
1 (0.5) 
0 (0) 
0.34 
0.39 
0.67 
0.32 
0.31 
Any grade 1 or 2 laboratory abnormality, n (%) 
  Anaemia 
  ALT elevation >1.25-5 times the upper normal limit 
116 (58.8) 
98 (49.8) 
47 (23.9) 
98 (48.3) 
80 (39.4) 
22 (10.8) 
0.03 
0.04 
<0.01 
Any grade 3 or 4 laboratory abnormality, n (%) 
  Anaemia 
  ALT elevation >5 times the upper normal limit 
25 (12.7) 
22 (11.2) 
3 (1.5) 
18 (8.9) 
13 (6.4) 
1 (0.5) 
0.22 
0.09 
0.30 
Hospitalisation, n (%) 22 (11.2) 18 (8.9) 0.44 
ALT: Alanine aminotransferase. 
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